to the endoplasmic reticulum (ER), where acyl coenzyme A : cholesterol acyltransferase (ACAT) resides. ACAT catalyzes the esterification of free cholesterol, so that modified or native LDL-derived free cholesterol is re-esterified at the ER, released into the cytoplasm, and stored as lipid droplets. These processes cause foamy transformation of the macrophages (4, 5) .
During our morphological analysis of foamy transformed macrophages, we discovered a unique, cholesterol-induced, functional endosomal organelle : ACAT1-positive late endosomes (ACAT1-LE). In this review article, we describe our discovery of ACAT1-LE and discuss the functional significance of this unique cholesterol-induced organelle. In addition, we describe the clinical significance of ACAT1-LE induction on the congenital endosomal storage disease--Niemann Pick disease type C (NPC).
ACAT
The presence of a cholesterol-esterifying enzyme in mammalian cells has been known since the 1960s. Its enzymatic activity was usually detected in microsomal fractions, so ACAT is said to reside in the ER. Chang et al. first cloned ACAT in 1993 (6) , and extensive genetic investigations then produced the cloned ACAT isozyme ACAT2 (after which the first cloned ACAT was renamed ACAT1) (7) . Most human somatic cells express ACAT1 ; in particular, macrophages, adrenal cortex cells, and sebaceous cells express a significant amount of ACAT1 (8). In contrast, ACAT2 expression is limited to the apical region of enterocytes, fetal hepatocytes, and welldifferentiated macrophages (9) (10) (11) . Under physiological conditions, ACAT functions in intracellular cholesterol homeostasis in mammalian cells, especially in macrophages and steroid hormone-producing cells ; in addition, it regulates lipoprotein synthesis in hepatocytes and enterocytes (5) . Artificial inhibition of ACAT enzymatic activity therefore causes impaired lipoprotein synthesis as well as ER stress-mediated apoptosis via free cholesterolinduced cell toxicity (12) .
In pathological situations, ACAT, by esterifying cholesterol, serves a critical function as a protector against free cholesterol-induced cell toxicity. The presence of foamy transformed macrophages in atherosclerotic plaques therefore indicates ACAT-dependent macrophage protection against massive cholesterol loading. Foamy transformed macrophages in atheromatous plaques, i.e. macrophages with massive cholesterol loading, continuously internalize modified LDL via scavenger receptors. The key issue for foamy transformed macrophages in atheromatous plaques relates to sufficient ACAT1 expression (mature macrophages express both ACAT1 and ACAT2, and 90% of enzymatic activity derives from ACAT1) (11) . In fact, a high-fat diet fed to atherogenic mice with ACAT1-null macrophages led to a reduced number of foamy transformed macrophages and consequently severe inflammation, which resulted in increased atheromatous plaque formation (13) . These data prompted us to question how macrophages protect themselves from cholesterol-induced cell toxicity. The answer to this basic question is ACAT1-LE.
ACAT1 VESICLES AND ACAT1-LE
As noted above, ACAT is an ER-resident enzyme. We confirmed the location of ACAT1 to be the tubular ER membrane in normal human macrophages ( Figure 1A , intact M ) (14) . Next, we tried to detect the ACAT1 signal in macrophages under cholesterol-rich conditions. Treatment with a cholesterol donor (acetylated LDL) caused the ACAT1 signal in human macrophages to appear on small vesicles approximately 100 nm in diameter ( Figure 1A , cholesterol-rich M ). The ER marker protein GRP78 also appeared on small vesicles after cholesterol donor treatment ( Figure 1B , cholesterol-rich M ). Furthermore, both ACAT1 and GRP78 signals correlated with each other before and after foamy transformation ( Figure 1C) , and the expression level of ACAT1 did not change before and after cholesterol donor treatment (data not shown). These data thus indicate that cholesterol-rich, foamy transformed macrophages produce ACAT1-positive vesicles via ER fragmentation.
ACAT is a representative allosteric enzyme whose enzymatic activity increases after cholesterol binds to its allosteric site. We thus believed that formation of ACAT1 vesicles would be related to allosteric regulation. A series of investigations of the significance of ACAT1 vesicle formation led to the discovery of ACAT1-LE. As Figure 2 shows, separate ACAT1 signals and signals of the late endosomal marker protein lysosomal-associated membrane protein 2 (LAMP2) were detected in macrophages with no lipid accumulation ( Human macrophages derived from peripheral blood monocytes with or without acetylated LDL treatment were subjected to immunoelectron microscopy (post-embedding method) and confocal laser scanning microscopy. (A) Immunoelectron microscopy after using ACAT1 -specific antibody. (B) Immunoelectron microscopy after using GRP78 (ER marker protein) -specific antibody. The inset in A is an enlarged image. Arrows indicate specific signals. (C) Confocal laser scanning microscopy after using ACAT1 -specific antibody (green) and GRP78 -specific antibody (red). Yellow in the merged image indicates a colocalization signal. Details are provided in the text. Adapted from references 9 and 14.
LAMP2 signal in foamy transformed macrophages (Figure 2A , cholesterol-rich M , Figure 2B ). The purified ACAT1-positive organelles from cholesterolrich macrophages contained LAMP2, but those from intact macrophages did not ( Figure 2C ), and immunoelectron microscopy confirmed the presence of the ACAT1 signal on beads containing phagosomal membranes from only foamy transformed macrophages ( Figure 2D) , not intact macrophages. These data thus indicate that foamy transformed macrophages form ACAT1-LE via ER fragmentation (14, 15) . 
ACAT1-LE AND CHOLESTEROL METABO-LISM
As described above, the late endosome is an organelle that contains free cholesterol derived from internalized LDL, and ACAT1 is an enzyme that esterifies free cholesterol. ACAT1-LE would therefore be an organelle that would re-esterify LDL-derived free cholesterol in loco. To demonstrate efficient cholesterol esterification at endosomes, we investigated cholesterol esterification kinetics in macrophages with ACAT1-LE. Figure 3A illustrates that intact macrophages required at least 2 hours to reesterify LDL-derived free cholesterol because of the complex intracellular cholesterol trafficking system described here, in the Introduction. In contrast, foamy transformed macrophages with ACAT1-LE esterified a significant amount of LDL-derived cholesterol within 30 minutes. This finding suggests efficient cholesterol esterification in ACAT1-LEpositive macrophages. To demonstrate directly that ACAT1-LE is the site of cholesterol esterification, we performed an experiment in which cholesterol egress was inhibited. U18666A is an amphiphilic amino-steroid that blocks free cholesterol egress from late endosomes by interfering with the cholesterol trafficking protein NPC1 (5) . Macrophages treated with U18666A showed negligible cholesterol esterification because no cholesterol reached the ER, where ACAT1 resides. In contrast, foamy transformed ACAT1-LE-positive macrophages esterified a significant amount of free cholesterol even in the presence of U18666A ( Figure 3B ). These data are direct evidence of cholesterol esterification at the ACAT1-LE, i.e. this unique organelle effectively esterified LDL-derived free cholesterol just after LDL hydrolysis at late endosomes. This finding stimulated us to pursue the therapeutic application of ACAT1-LE to NPC.
NPC AND ACAT1-LE INDUCTION
Niemann-Pick disease is a congenital lysosomal storage disease characterized by massive sphingomyelin accumulation. This disease was traditionally classified as type A to type E according to its clinical manifestations, but molecular analysis of the disease led to reclassification of types according to two criteria : Niemann-Pick disease type A, with an acid sphingomyelinase deficiency, and NPC, with an NPC1 protein deficiency (16) . Deletion of the NPC1 protein causes free cholesterol accumulation in late endosomes, which results in inhibition of acid sphingomyelinase. As a result, NPC accumulates free cholesterol as well as sphingomyelin, with consequent cell injury. One possible therapeutic strategy for NPC is using methyl-β-cyclodextrin (mβCD), which is a cyclic oligosaccharide, to incorporate hydrophobic molecules such as cholesterol. mβCD is internalized via pinocytosis, remains at late endosomes, and removes accumulated free cholesterol from late endosomes and plasma membranes of cells with the NPC phenotype (npc-/-) (17) . Administration of mβCD to npc-/-mice ameliorated tissue injury and prolonged survival, and this beneficial effect was also observed in patients with NPC (18, 19) . 
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In contrast to the approach of removing cholesterol by using mβCD, we believed that inducing ACAT1-LE in npc-/-macrophages would also effectively reduce the intracellular cholesterol level by means of cholesterol esterification. Indeed, treatment with mβCD-cholesterol complex (mβCD-cho), a cholesterol donor, effectively produced ACAT1-LE-positive npc-/-macrophages. These ACAT1-LEpositive npc-/-macrophages showed significant cholesterol esterification and effective reduction of the intracellular cholesterol level ( Figure 4A ). In addition, administration of mβCD-cho to npc-/-neonate mice effectively extended their survival to the same level as did conventional cholesterol remover treatment ( Figure 4B ) (20) . These data thus show that induction of ACAT1-LE in patients with NPC may be an alternative therapeutic approach ( Figure  5) .
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CLOSING REMARKS
The question of whether intracellular ACAT1 localization would change under cholesterol-rich conditions (i.e. substrate-rich conditions for ACAT1) in human macrophages led us to discover ACAT1-LE and an alternative treatment strategy for NPC. Although in this review we did not mention the ACAT1-LE degradative pathway, ACAT1-LE has an impaired degradative pathway that depends on ACAT enzymatic activity. The late endosome is not only the principal organelle in the intracellular degradative pathway but is also the sorting compartment for protein synthesis. Therefore, ACAT1-LE-positive foamy transformed macrophages may manifest impaired protein sorting, which in hyperlipidemic conditions would result in disturbed protein synthesis such as cytokine production. Further research must clarify the details of ACAT1-LE function and its medical significance.
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